The U.S. Centers for Disease Control and Prevention (CDC) on Tuesday recommended new COVID-19 boosters from Pfizer and Moderna for all people ages 6 months and older, NBC News reports. The recommendation follows the FDA‘s endorsement of the shots earlier this week.
With the new CDC recommendation, the shots should start to roll out across the U.S. in the coming days, according to the CDC.
Pfizer and Moderna‘s new shots target the Omicron XBB.1.5 variant. Nearly all circulating cases are related to that strain, according to U.S. officials.
The rollout comes amid a recent uptick in cases in the U.S., and ahead of a potential “tripledemic” of influenza, COVID-19 and respiratory syncytial virus, officials have warned.
China’s BioRay Pharmaceutical has received approval for its biologic zuberitamab for the treatment of CD20-positive diffuse large B-cell lymphoma from the country’s National Medical Products Administration (NMPA).
With the approval, BioRay gave its new cancer drug the trade name Anruixi. The drug turned in positive results in trials of various stages, the company said in a release, including in a head-to-head versus Roche’s Rituxan.
Anruixi becomes the first domestically developed Class I anti-CD20 drug to be approved in China. It succeeds BioRay’s Anruize as the company’s “next major product.”
BioRay is studying its new medicine in autoimmune diseases, as well.
